Patents by Inventor Ralph Tiedt

Ralph Tiedt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE
    Publication number: 20220184090
    Abstract: The present invention relates to pharmaceutical products comprising a combination of (i) a MET inhibitor and (ii) an EGFR inhibitor, or a pharmaceutically acceptable salt thereof, respectively, or a prodrug thereof, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related invention embodiments.
    Type: Application
    Filed: July 23, 2021
    Publication date: June 16, 2022
    Inventors: Ralph TIEDT, Christian CHATENAY-RIVAUDAY, Moriko ITO, Mikhail AKIMOV, Bin PENG, Ying GONG
  • Combination products with tyrosine kinase inhibitors and their use
    Patent number: 11096947
    Abstract: The present invention relates to pharmaceutical products comprising a combination of (i) a MET inhibitor and (ii) an EGFR inhibitor, or a pharmaceutically acceptable salt thereof, respectively, or a prodrug thereof, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related invention embodiments.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: August 24, 2021
    Assignee: Novartis AG
    Inventors: Ralph Tiedt, Christian Chatenay-Rivauday, Moriko Ito, Mikhail Akimov, Bin Peng, Ying Gong
  • COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE
    Publication number: 20200316081
    Abstract: The present invention relates to pharmaceutical products comprising a combination of (i) a MET inhibitor and (ii) an EGFR inhibitor, or a pharmaceutically acceptable salt thereof, respectively, or a prodrug thereof, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related invention embodiments.
    Type: Application
    Filed: June 18, 2020
    Publication date: October 8, 2020
    Inventors: Ralph Tiedt, Christian Chatenay-Rivauday, Moriko Ito, Mikhail Akimov, Bin Peng, Ying Gong
  • Combination Products with Tyrosine Kinase Inhibitors and their Use
    Publication number: 20180098995
    Abstract: The present invention relates to pharmaceutical products comprising a combination of (i) a MET inhibitor and (ii) an EGFR inhibitor, or a pharmaceutically acceptable salt thereof, respectively, or a prodrug thereof, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related invention embodiments.
    Type: Application
    Filed: December 13, 2017
    Publication date: April 12, 2018
    Inventors: Ralph Tiedt, Christian Chatenay-Rivauday, Moriko Ito, Mikhail Akimov, Bin Peng, Ying Gong
  • Combination Products with Tyrosine Kinase Inhibitors and their Use
    Publication number: 20150297604
    Abstract: The present invention relates to pharmaceutical products comprising a combination of (i) a MET inhibitor and (ii) an EGFR inhibitor, or a pharmaceutically acceptable salt thereof, respectively, or a prodrug thereof, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes commercial packages and related invention embodiments.
    Type: Application
    Filed: April 3, 2013
    Publication date: October 22, 2015
    Applicant: Novartis AG
    Inventors: Ralph Tiedt, Christian Chatenay-Rivauday, Monko Ito, Mikhail Akimov, Bin Peng, Ying Gong
  • Tyrosine Kinase Inhibitor Combinations and their Use
    Publication number: 20150051210
    Abstract: The invention relates to pharmaceutical combination product comprising (i) a MET inhibitor and (ii) an FGFR inhibitor, or a pharmaceutical acceptable salt thereof, respectively, or a prodrug thereof, respectively, and at least one pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 1, 2013
    Publication date: February 19, 2015
    Applicant: Novartis AG
    Inventors: Ralph Tiedt, Alan Buckler, Fred Harbinski, Sneha Sanghavi, Douglas Jeffery, Christopher Wilson